Biogen’s Post

Addressing health disparities is a crucial aspect of implementing value-based and evidence-based care in healthcare systems. By recognizing and targeting the underlying factors that contribute to unequal access and outcomes, such as socio-economic status, race, and geography, healthcare providers can work towards delivering more equitable care. Value-based care, with its emphasis on quality and effectiveness, aligns well with the goal of reducing health disparities. It encourages healthcare professionals to focus on preventive measures and coordinated treatment plans, ensuring that all patients receive the highest standard of care regardless of their background. Additionally, evidence-based care relies on data and research to guide clinical decisions, helping to identify and implement interventions that have been proven effective in diverse populations. By integrating these approaches, healthcare systems can make significant strides in narrowing health disparities and promoting health equity for all individuals. Dr. Michael Poku, chief clinical officer at Equality Health, talks tech needed to successfully tackle inequity ...

Sharing this important and informative article with my network. If you work in the life sciences industry, this is a good read. We can all play a role in achieving health equity! #healthequity https://lnkd.in/gZc-fJFZ

“Remembering the contribution of health activists like Amit Sengupta and David Sanders to the right-to-health movement is crucial for advancing the struggle for access to medicines” Amitabha Sarkar, PhD (People’s Health Movement).  🛣 In the current framework, “access and innovation do not have a linear relationship, they don’t really come together.” To change that, we need to rethink the trajectory of governance in access to medicines, with increased participation and autonomy of self-governance being a priority. All aspects of pharmaceutics should be treated as Commons, as something that is collective ownership, built from the bottom-up. Until today, the traditional stream of politics prevailed over a more radical change of discourse, including in WHO discussions and documents. Public Sector Strengthening Pathway is urgently needed, including capacity development, epidemiological access mapping, restructuring knowledge management, public investment in public-public partnerships, and more. #publicpharmaeurope

How serious is US FDA about advancing health equity? Short answer - Quite serious. USFDA's Center for Devices and Radiological Health (CDRH) has outlined its 2022-2025 Strategic Priorities and "Advancing Health Equity" is one of them. Here are CDRH's three Strategic Priorities for 2022-2025: 🎯 Promote a Modern and Diverse Workforce 🎯 Enhance Organizational Agility and Resilience 🎯 Advance Health Equity Consistent with their strategic priority of Advancing Health Equity - CDRH has also published a "Request for Public Comment" to increase access to at-home use medical technologies. 🏠💡 The call for public comment quotes "Access to devices outside a clinical care setting may help bridge the gap by bringing health care directly to patients, wherever they are – at home, at work, in cities, in rural communities." Want to contribute? Here is the link to access the Request for Public Comment is here - https://lnkd.in/dJkpYEJR

Did you know? Diverse participation in clinical trials is a game-changer for health equity. Here is a list of the positive results: Better Insights: Various backgrounds in trials gives accurate insights into treatment effectiveness. Tailored Care: Diverse trials lead to personalized treatments. Health equity means treatments that fit you. Bridge the Gap: Say no to health disparities. Diverse trials help us tackle unequal impacts. Let's make quality healthcare accessible to all. Uncover All: Diverse trials reveal hidden effects, ensuring safety. Join us as we pursue health equity! Together, we create a fairer, healthier future. Visit our website for membership and partnership opportunities - https://lnkd.in/gxZhpcCg

A new article published in [Fierce Biotech] features a discussion between two leaders supporting the Rise to Health Coalition, Fritz Bittenbender (Genentech) and Dr. Kedar Mate (IHI). In their conversation, Bittenbender and Mate discuss why an industry-wide approach to health equity is necessary, the role of biotech in advancing health equity, and how health equity is a moral and business imperative.    Read all they had to say at https://lnkd.in/dt8qeGXX.

12 health systems recently united to support the ongoing journey for health equity. Explore these health systems and their strategy today: https://lnkd.in/e2YMGeZ4 #healthequity | #healthcare | #technology

Aligning resources and approaches will help us move farther and faster. Curious how you can join the effort? Check out Rise To Health Coalition to learn more.